Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 2
1986 1
1987 1
1989 7
1990 3
1991 2
1993 4
1994 1
1995 1
1997 2
1998 4
1999 2
2000 3
2001 2
2003 3
2004 4
2005 3
2006 2
2007 2
2008 3
2009 1
2010 1
2011 2
2012 1
2013 2
2014 2
2015 3
2016 4
2017 5
2018 2
2019 2
2020 4
2021 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Gotti M, Sciarra R, Pulsoni A, Merli F, Luminari S, Zerbi C, Trentin L, Re A, Rusconi C, Viviani S, Rossi A, Cocito F, Botto B, Meli E, Pinto A, Dogliotti I, Gini G, Puccini B, Ricci F, Nassi L, Fabbri A, Liberati AM, Merli M, Filippi AR, Bonfichi M, Zoboli V, Tartaglia G, Annechini G, D'Elia GM, Del Giudice I, Alvarez I, Visentin A, Pravato S, Dalceggio D, Pagani C, Ferrari S, Cristinelli C, Lazic T, Ferretti VV, Ricardi U, Arcaini L. Gotti M, et al. Among authors: bonfichi m. Hemasphere. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837. eCollection 2023 Apr. Hemasphere. 2023. PMID: 37034003 Free PMC article.
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Santoro A, Mazza R, Pulsoni A, Re A, Bonfichi M, Zilioli VR, Zanni M, Merli F, Anastasia A, Luminari S, Annechini G, Gotti M, Peli A, Liberati AM, Di Renzo N, Castagna L, Giordano L, Ricci F, Carlo-Stella C. Santoro A, et al. Among authors: bonfichi m. Blood Adv. 2020 Jan 14;4(1):136-140. doi: 10.1182/bloodadvances.2019000984. Blood Adv. 2020. PMID: 31935284 Free PMC article. Clinical Trial.
Treatment of relapsed and refractory acute myeloid leukemia in adults.
Lazzarino M, Morra E, Alessandrino EP, Merante S, Bernasconi P, Bonfichi M, Caldera D, Bernasconi C. Lazzarino M, et al. Among authors: bonfichi m. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:121-3. Bone Marrow Transplant. 1989. PMID: 2653487 Review. No abstract available.
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS.
Stefoni V, Marangon M, Re A, Lleshi A, Bonfichi M, Pinto A, Bianchetti N, Pellegrini C, Argnani L, Zinzani PL. Stefoni V, et al. Among authors: bonfichi m. Haematologica. 2020 Oct 1;105(10):e512. doi: 10.3324/haematol.2019.243170. Haematologica. 2020. PMID: 33054094 Free PMC article. Clinical Trial. No abstract available.
FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients.
Fracchiolla NS, Artuso S, Cortelezzi A, Pelizzari AM, Tozzi P, Bonfichi M, Bocchio F, Gargantini L, De Rosa E, Vighi GD, Prestini L, Sammassimo S, Frungillo N, Pasquini MC, Ragazzi A, Boghi D, Pastore A, Lanzi E, Gritti G, Quaresmini G, Voltolini S, Gaiardoni R, Corti C, Vilardo MC, La Targia ML, Berini G, Magagnoli M, Bacci C, Consonni D, Rivolta AL, Muti G. Fracchiolla NS, et al. Among authors: bonfichi m. Hematol Oncol. 2018 Feb;36(1):299-306. doi: 10.1002/hon.2451. Epub 2017 Aug 3. Hematol Oncol. 2018. PMID: 28771763
77 results